Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal

被引:15
作者
Carli, G. [1 ]
Farsi, A. [1 ]
Chiarini, F. [1 ]
Lippolis, D. [2 ]
Cortellini, G. [2 ]
机构
[1] Azienda USL Toscana Centro, SOS Allergol & Immunol, Pistoia, Italy
[2] Osped Infermi, UOC Med Interna & Reumatol, Allergol, Rimini, Italy
关键词
novel oral anticoagulants or non-vitamin K oral anticoagulants (NOACs); rivaroxaban; apixaban; edoxaban; dabigatran; hypersensitivity; LEUKOCYTOCLASTIC VASCULITIS; DABIGATRAN; THROMBOCYTOPENIA; SKIN;
D O I
10.23822/EurAnnACI.1764-1489.80
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly being used in hospital and outpatient settings as safe alternatives to warfarin. Hypersensitivity reactions have been described for NOACs and can be classified according to Gell and Coombs. We reviewed case reports of possible drug hypersensitivity reactions, noticing a predominance of delayed reactions (both mild and severe) and the absence of cross-reactions to warfarin and low molecular weight heparins. International experience on diagnostic tests is lacking. The vast majority of authors refer to probability scores and rely on biopsy to classify vasculitis and rule out differential diagnoses. We propose to adapt available tests to confirm the patient's reactivity to new anticoagulants. Among in vivo tests, patch testing revealed promising in delayed reactions.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 39 条
  • [1] Angioedema due to the new oral anticoagulant rivaroxaban
    Altin, Cihan
    Ozturkeri, Ovgu Anil Yakin
    Gezmis, Esin
    Askin, Ulku
    [J]. ANNALS OF CARDIAC ANAESTHESIA, 2014, 17 (02) : 173 - 174
  • [2] An J, 2017, BMJ CASE REP, V2017
  • [3] [Anonymous], 2010, BOEHRINGER INGELHEIM
  • [4] Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management
    Aster, R. H.
    Curtis, B. R.
    McFarland, J. G.
    Bougie, D. W.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (06) : 911 - 918
  • [5] Severe Drug-Induced Skin and Liver Injury from Rivaroxaban
    Barrett, Patrick
    Vuppalanchi, Raj
    Masuoka, Howard
    Chalasani, Naga
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (06) : 1856 - 1858
  • [6] Beasley N, CLIN REV APPL TYPE S
  • [7] Cakmac MA, 2014, EUR REV MED PHARMACO, V18, P2595
  • [8] XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Hess, Susanne
    Kirchhof, Paulus
    Kuhls, Silvia
    van Eickels, Martin
    Turpie, Alexander G. G.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (14) : 1145 - 1153
  • [9] Chaaya G, 2016, ANN ALLERG ASTHMA IM, V116, P577, DOI 10.1016/j.anai.2016.03.012
  • [10] Chiasson CO, 2017, CAN J HOSP PHARM, V70, P301